NewLink Genetics to present Phase 2 data of HyperAcute-Pancreas immunotherapy for resected pancreatic cancer

NewsGuard 100/100 Score
May 20 2010

NewLink Genetics Corporation today announced that preliminary data from its Phase 2 clinical trial evaluating the effect of HyperAcute®-Pancreas immunotherapy in patients with resected pancreatic cancer will be presented during a poster session at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting held June 4-8, 2010 in Chicago, Illinois. A summary of the company's ASCO presentation is below.

Hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer improves disease-free and overall survival: preliminary analysis of phase 2 data

  • General poster session: Sunday, June 6, 2010, 2:00 p.m. – 6:00 p.m. Central Time (CT)
  • Abstract # 54004 (poster board # 20F)
  • First Author: Dr. Jeffrey M. Hardacre, University Hospitals Case Medical Center, Cleveland, Ohio

SOURCE NewLink Genetics Corporation

Posted in: Medical Procedure News | Medical Condition News

Tags: , , , , , , , , , , ,

Comments (0)

Suggested Reading

Breast cancer survivors at higher risk of developing second cancers
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer
FDA approval of Anktiva heralds a new era in the treatment of BCG-unresponsive non–muscle-invasive bladder cancer
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes
New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact
Study links air pollution to increased colorectal cancer risk through DNA changes
Breakthrough imaging method enhances precision in prostate cancer treatment

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer